Stockrabit · Analysts
Questions across 11 calls

Bansi Desai

Firm not listed in source transcripts

Lupin Limited

Lupin Limited CC-Feb26.pdf · 2026-02-13
The first question is on the overall biosimilar landscape in the U.S. We see recent developments, which are all aimed at improving affordability and accessibility, which is good, structurally positive for us as well. But at the same time, it is also going t o make market more competitive. So, how should we think about what will be those key factors which will determine our success? You mentioned about having that cost advantage, but I'm assuming a lot of Indian companies would have that. So that's number one. And the second is we also see PBMs having their own brands or bringing their own labels in the space. That adds to the competition, right? How do you think about that relationship?
And just a second question, which is a clarification on Mirabegron. If I think about USD 90 million of payment, is it more or less what we have earned so far on this product or much lower than what we'd have made? That's number one. Second, with the settlement until September '27, does it mean that we should not anticipate any generic players to come in this period, or they could come and settle with similar terms, that is paying royalty, etcetera, on the sales that they could do?

Max Healthcare Institute Limited

Max Healthcare Institute Limited CC-Feb26.pdf · 2026-02-06
So, my first question is on the growth of our existi ng hospital beds. So tradition ally, if we see barring any seas onality impact, you still managed to see good low teens kind of growth for our existing beds despite the fact that they have been operating at like 75% plus occupancy levels, partially, it could be because of higher onco share or robotics, etc., which you mentioned? But as we go f orward, do you think theoretically, this has to normalize at some point in time? And for us, therefore, what cou ld be the levers which can keep the growth momentum high over the next 2, 3 years?
Yes. So Abhay, actually, I was just trying to say that if I act ually look at this quarter and if I map it over a 2 -year CAGR, this number still suggest s a 20% CAGR over 2 years. So, if I remove that seasonality impact, and this is beside the fact that we have not added as many beds? So, what I wa s trying to understand is that it does mean that ou r existing beds are still growin g well in that low -teens rate. And we have seen that peers that most mature beds beyond a point once you reached your optimal occupancy levels, will probably come down to high single -digit kind o f growth rates, etc . So, I was just trying to understand that from our side, if seasonality were to remain favorable, then do we continue to see the kind of growth that we have seen?

Global Health Limited

Global Health Limited CC-Feb26.pdf · 2026-02-05
Thanks for taking my question. So, firstly, on Noida, how should we think about the losses from here on? I am assuming these would be the peak kind of losses that we report in the quarter given we have added doctors and a large part of commissioning expenses would be sitting in this quarter , and therefore, as the unit ramps up, should we see losses coming down? And also, given the fact that we are expected to add another 200 + beds here over the next one year, how should we see the loss trajectory?
And when we think of adding 200 beds here, I would assume those would largely get absorbed with these 300 beds ramping up by that time?
Global Health Limited CC-Dec24.pdf · 2025-02-05
Thanks for taking my question. My first question is on Gurgaon facility. So, we have seen a decent improvement in occupancy here year-over-year for last couple of years. We have added 50 beds here. How should we think about optimal occupancy for this particular unit? I understand our infrastructure layout for Gurgaon Hospital and for that matter, all our hospitals is quite different compared to peers. So, how should we think abou t optimal occupancy levels? Will it be difficult for us to reach 70 %-75% occupancy levels or do you think that's achievable with our specialties or exposure to specialties that we have?
Got it. So, the reason I asked is that in the last 2-3 years, if I see, our average length of stay has remained pretty much the same. So, what probably has allowed us, so to that extent, the inpatient volume growth is probably reflected in the occupancy increase, except for the fact that you mentioned that, you know, some of the chemotherapy beds etc. are not included in our occupancy numbers?

Anthem Biosciences Limited

Anthem Biosciences Limited CC-Feb26.pdf · 2026-02-05
Hi. Thanks for taking my question. My first question is on our pipeline, if you can comment on how this has grown, particularly early phase, Phase 1, Phase 2. We know Phase-3, out of 10 molecules, 4 have been commercialized. So, probably, you would have 6 in the Phase-3 as of today, if you can just update on that. Out of the early phase, any indication as to, how many of them are likely to move into Phase-3, in your view, in next 1 to 2 years?
We generally hear, improvement in the biotech funding environment, in the recent months. Also, there has been a lot of pent -up demand, given the funding environment has been weak all together in the last 2-3 years. So, are we likely to see, benefits of that, you know, trickling to us as we go ahead? Are we likely to see more expansion of our pipeline on the phase products, especially?
Anthem Biosciences Limited CC-Nov25.pdf · 2025-11-10
Thanks for taking my question. Firstly, this quarter, we saw our specialty ingredients business reporting a decline. Could you help us understand what was the reason and how should we think about the specialty business growth for the rest of the year? My second question is on our costs. We saw both employee expenses and other expenses decline YoY. I am assuming some part of it would be because of ESOP costs being in the base. But if you could help us understand, is this the sustainable base from here on?
All right. Just one clarification to this ESOP cost, Rs. 4 Cr per quarter, is this likely to also come down starting next year?

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited CC-Feb26.pdf · 2026-02-04
Yes, hi. Thanks and congratulations on a strong set of numbers. So just two questions. So firstly, on our international markets growth, which has been pretty robust. I assume this also has seen benefits of favourable currency across markets. So if you could just comment on whether we are seeing those benefits at our gross margin levels as well? And therefore, as and when these currencies normalize over the next few quarters, how should we think about our gross margins? Because our in-licensing component probably would continue to grow Sanofi portfolio. You also have Novo Nordisk products. So I'm just thinking through how should we think about gross margins in that light once the currency normalizes?
All right. And for Amphotericin B market, which you mentioned EUR100 million, if you can also talk about the competitive landscape. I understand you're the only generic approved at this point in time, but how do you see competition evolving over the next few years?
Emcure Pharmaceuticals Limited CC-Jun24.pdf · 2024-08-14
My first question is on Canada business. If you can help us understand on a steady -state basis, how should we think about growth in this market, both for Mantra and ex-Mantra? And if I understand correctly, the market growth in Canada probably would be in single digits. So, what is going to be driving growth for us? Is it going to be new product launches ? Or if you can comment on pricing, volume, that will be great.
And as I understand the profitability here in this market is way superior than other international markets for us. So, should we expect that to continue?

Alkem Laboratories Limited

Alkem Laboratories Limited CC-Mar25.pdf · 2025-05-29
Yes, hi. Thanks for the opportunity. My question is on Enzene US business of ours. So if you can just qualitatively tell us how the discussions are progressing with clients, what is the interest level in general especially in the existing backdrop of reshoring manufacturing in the US. And secondly, you mentioned that it will take some time for you to completely utilize this capacity. if you could give us some indication of what that could be. I mean, is it 2-3 years or could it be more than that?
And in your assessment, would you beli eve you would need to further enhance your CAPEX based on the visibility that you have?

Rainbow Childrens Medicare Limited

Rainbow Childrens Medicare Limited CC-Sep23.pdf · 2023-10-31
My question is on margins in this quarter . So, despite sharp decline in occupancies , we have reported margin of 35% plus . I understand there was a benefit of case mix, also cost control , which would have driven these margins. But just trying to understand, had this quarter been a normal quarter, would our margins be any different? Just trying to understand, you know, is case mix a bigger driver of margins or occupancy for us?
That's good to hear. And my second question is on occupancy. So, for the newer beds, we have reported 35% occupancy. So, if you were to adjust for the new beds which got commissioned in the last four quarters, what would have been the occupancies like for that cluster?